Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1047 first-in-human dose-escalation and expansion study in advanced B7H4-expressing solid tumors
NL-OMON56075Phase 2Not yet recruiting
- Sponsor
- Genmab
- Start
- Jun 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of GEN1047 in breast cancer, endometrial cancer (EC), ovarian cancer and 1 more (2 arms), sponsored by Genmab. Primary endpoint: Objective response rate. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
GEN1047
03
Conditions
breast cancerendometrial cancer (EC)ovarian cancerPulmonary squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON56075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56075.